Targets › ADV
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Mar 2028.
Open in Phaseline: the race on ADV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tobias Feuchtinger | Multivirus (CMV, EBV, AdV)-specific T cells Adoptive transfer of multivirus-specific T cells targeting CMV, EBV, and AdV | CMV, EBV, ADV | Phase 3 | AdV Infection | Mar 2028 |
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.